Abstract: Pyridazine compounds for inhibiting NaV1.8 and methods for treating a condition, disease, or disorder associated with an increased NaV1.8 activity or expression are disclosed.

Abstract: The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface receptor, such as a folate receptor. The cell surface folate binding compound can trigger the receptor to internalize into the cell a bound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor, e.g., folate receptor. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided herein are methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.

Abstract: Systems and methods for making clear ice are described. The system may include a housing comprising a plurality of elongate troughs. Each of the plurality of elongate troughs may have at least one flume surface wall in thermal communication with a cooling source while the housing is submerged in a fluid bath. The system may further include at least one fluid intake disposed to provide a flow of fluid to the housing and a means for distributing the flow of fluid from the at least one fluid intake into the plurality of elongate troughs while maintaining a substantially laminar fluid flow and substantially equal fluid pressure along the plurality of elongate troughs while the housing is submerged in the fluid bath and during a freezing operation of the device.

Abstract: An enterprise inventory management system, and methods of use thereof, utilizing novel functionalities. The system includes a centralized global inventory database subsystem for cataloging a plurality of inventory items from a plurality of remote physical locations, each of the items identified by at least a unique identification code; and, a plurality of localized radio frequency identification (RFID) interrogator subsystems associated with a corresponding plurality of remote physical locations, wherein each of the localized RF interrogator subsystems is operative to read RFID tags associated with ones of the plurality of inventory items located at its associated physical location, wherein each of the RFID tags is programmed with at least a unique identification code for its associated item.

Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.

Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.

Abstract: Biological macromolecules have tremendous potential for the treatment of disease of the central nervous system (CNS), however, the presence of the blood brain barrier (BBB) makes achieving a therapeutically relevant antibody concentration extremely challenging. Antibodies with enhanced neutral pH affinity for the neonatal Fc receptor demonstrate improved accumulation in the brain. Variants disclosed herein also enhanced exposure in engineered mouse models. Using an anti-BACE1 antibody, these Fc variants significantly reduced the levels of brain Abeta.

Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.

Abstract: Disclosed herein is an optogenetics-based gene therapy that involves channelrhodopsin fusion proteins having an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS) that can effectively target the fusion protein to an inner mitochondria membrane, and a channelrhodopsin ion channel domain that can change the mitochondrial membrane potential (??m) when light is present. The disclosed optogenetics-based gene therapy system can in some embodiments further involve luciferase fusion proteins to stimulate the channelrhodopsin without reliance on external light that has an outer mitochondrial membrane-mitochondrial localization signal (OMM-MLS) that can effectively target the luciferase fusion protein to an outer mitochondrial membrane, and a luciferase protein that can produce a bioluminescence in the presence of a luciferase substrate.

Abstract: The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.

Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.

Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.

Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.

Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.

Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.

Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.

Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.

Abstract: The present invention relates to anti-trans-ferrin receptor antibodies and methods of their use.

Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.

Abstract: The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.